Tag: Dr John Reed

dupilumab

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.

Connect with Us

37,536FansLike
492FollowersFollow
2,625FollowersFollow
5,417FollowersFollow
38SubscribersSubscribe